NCT02426541View on ClinicalTrials.gov

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

April 28, 2016

Study Completion Date

April 28, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

DRUG

Placebo

Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

Trial Locations (1)

Unknown

Research Site, Turku

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Antaros Medical

INDUSTRY

collaborator

Bioventure Hub

UNKNOWN

collaborator

43183 Mölndal

UNKNOWN

collaborator

Sweden

UNKNOWN

lead

AstraZeneca

INDUSTRY